Pajjiż: Singapor
Lingwa: Ingliż
Sors: HSA (Health Sciences Authority)
LIGNOCAINE HCl ANHYDROUS
DCH AURIGA SINGAPORE
N01BB02
50 mg/5 ml
INJECTION
LIGNOCAINE HCl ANHYDROUS 50 mg/5 ml
INTRADERMAL
Prescription Only
ASTRAZENECA PTY LTD
ACTIVE
1991-04-05
NAME OF DRUG The active ingredient in XYLOCAINE is lignocaine hydrochloride. The CAS number for lignocaine hydrochloride, monohydrate is 6108-05-0. The chemical name for lignocaine hydrochloride is 2-Diethylaminoaceto-2’6’-xylidide. The Australian Approved Name is lignocaine hydrochloride. The chemical structure of lignocaine is: DESCRIPTION Lignocaine is classed as a membrane stabilising agent and is a local anaesthetic of the amide type. It is extremely stable and can be sterilised by autoclaving, repeated a maximum of two times if necessary. Plain aqueous solutions are sterile, isotonic and contain lignocaine hydrochloride, sodium chloride, sodium hydroxide for pH adjustment and water for injections. XYLOCAINE solutions contain no antimicrobial agent and should be used only once and any residue discarded. Plain aqueous solutions of lignocaine hydrochloride have a pH of 5.0-7.0 (approx.). Lignocaine base has a pKa of 7.85 (25°C), an oil/water coefficient of 2.9 and a molecular weight of 234.3. PHARMACOLOGY Lignocaine, like other local anaesthetics, causes a reversible blockade of impulse propagation along nerve fibres by preventing the inward movement of sodium ions through the nerve membrane. Local anaesthetics of the amide type are thought to act within the sodium channels of the nerve membrane. Local anaesthetic drugs may have similar effects on excitable membranes in the brain and myocardium. If excessive amounts of drug reach the systemic circulation rapidly, symptoms and signs of toxicity will appear, emanating mainly from the central nervous system and cardiovascular systems. Central nervous system toxicity usually precedes the cardiovascular effects as it occurs at lower plasma concentrations. Direct effects of local anaesthetics on the heart include slow conduction, negative inotropism and eventually cardiac arrest. Indirect cardiovascular effects, e.g. hypotension and bradycardia, may occur after epidural or spinal administration depending on the extent of the concomitant sympathetic block. Pharm Aqra d-dokument sħiħ
XYLOCAINE INJECTION 1% (5 ML) Lignocaine Hydrochloride PRODUCT INFORMATION Injection solution for the production of local or regional anaesthesia NAME OF DRUG The active ingredient in XYLOCAINE is lignocaine hydrochloride. The CAS number for lignocaine hydrochloride, monohydrate is 6108-05-0. The chemical name for lignocaine hydrochloride is 2-Diethylaminoaceto-2’6’-xylidide. The Australian Approved Name is Lidocaine (lignocaine hydrochloride. The chemical structure of lignocaine is: DESCRIPTION Lignocaine is classed as a membrane stabilising agent and is a local anaesthetic of the amide type. It is extremely stable and can be sterilised by autoclaving, repeated a maximum of two times if necessary. Plain aqueous solutions are sterile, isotonic and contain lignocaine hydrochloride, sodium chloride, sodium hydroxide for pH adjustment and water for injections. XYLOCAINE solutions contain no antimicrobial agent and should be used only once and any residue discarded. Plain aqueous solutions of lignocaine hydrochloride have a pH of 5.0-7.0 (approx.). Lignocaine base has a pKa of 7.85 (25°C), an oil/water coefficient of 2.9 and a molecular weight of 234.3. PHARMACOLOGY Lignocaine, like other local anaesthetics, causes a reversible blockade of impulse propagation along nerve fibres by preventing the inward movement of sodium ions through the nerve membrane. Local anaesthetics of the amide type are thought to act within the sodium channels of the nerve membrane. Local anaesthetic drugs may have similar effects on excitable membranes in the brain and myocardium. If excessive amounts of drug reach the systemic circulation rapidly, symptoms and signs of toxicity will appear, emanating mainly from the central nervous system and cardiovascular systems. Central nervous system toxicity usually precedes the cardiovascular effects as it occurs at lower plasma concentrations. Direct effects of local anaesthetics on the heart include slow conduction, negative inotropism and eventually cardiac arrest. Indirect cardiovascular eff Aqra d-dokument sħiħ